WallStSmart

Healthcare Triangle Inc (HCTI)vsMerck & Company Inc (MRK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 328051% more annual revenue ($65.77B vs $20.04M). MRK leads profitability with a 13.6% profit margin vs -69.7%. HCTI trades at a lower P/E of 0.0x. MRK earns a higher WallStSmart Score of 50/100 (D+).

HCTI

Hold

41

out of 100

Grade: D

Growth: 5.3Profit: 2.0Value: 6.7Quality: 4.5
Piotroski: 3/9Altman Z: -2.84

MRK

Hold

50

out of 100

Grade: D+

Growth: 3.3Profit: 8.0Value: 2.7Quality: 5.0
Piotroski: 3/9Altman Z: 2.27
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for HCTI.

MRKSignificantly Overvalued (-40.6%)

Margin of Safety

-40.6%

Fair Value

$80.96

Current Price

$128.43

$47.47 premium

UndervaluedFair: $80.96Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

HCTI4 strengths · Avg: 9.8/10
P/E RatioValuation
0.0x10/10

Attractively priced relative to earnings

Price/BookValuation
0.1x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
166.1%10/10

Revenue surging 166.1% year-over-year

Debt/EquityHealth
0.219/10

Conservative balance sheet, low leverage

MRK3 strengths · Avg: 9.3/10
Market CapQuality
$283.78B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
38.6%10/10

Strong operational efficiency at 38.6%

Free Cash FlowQuality
$2.93B8/10

Generating 2.9B in free cash flow

Areas to Watch

HCTI4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$4.44M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-26.5%2/10

ROE of -26.5% — below average capital efficiency

MRK4 concerns · Avg: 3.5/10
P/E RatioValuation
32.4x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
4.9%4/10

4.9% revenue growth

Debt/EquityHealth
1.073/10

Elevated debt levels

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : HCTI

The strongest argument for HCTI centers on P/E Ratio, Price/Book, Revenue Growth. Revenue growth of 166.1% demonstrates continued momentum.

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.

Bear Case : HCTI

The primary concerns for HCTI are EPS Growth, Market Cap, Piotroski F-Score.

Bear Case : MRK

The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.

Key Dynamics to Monitor

HCTI profiles as a hypergrowth stock while MRK is a value play — different risk/reward profiles.

HCTI carries more volatility with a beta of 1.05 — expect wider price swings.

HCTI is growing revenue faster at 166.1% — sustainability is the question.

MRK generates stronger free cash flow (2.9B), providing more financial flexibility.

Bottom Line

MRK scores higher overall (50/100 vs 41/100). Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Healthcare Triangle Inc

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

Healthcare Triangle, Inc. is a healthcare information technology company. The company is headquartered in Pleasanton, California.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Want to dig deeper into these stocks?